Northwest Biotherapeutics (OTCMKTS:NWBO) Share Price Breaks Below Two Hundred Day Moving Average – Should You Sell?

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $0.19 and traded as low as $0.1480. Northwest Biotherapeutics shares last traded at $0.1537, with a volume of 1,512,806 shares changing hands.

Northwest Biotherapeutics Stock Up 0.9%

The stock has a 50-day moving average of $0.17 and a 200 day moving average of $0.19. The stock has a market cap of $266.76 million, a PE ratio of -0.01 and a beta of -0.62.

Northwest Biotherapeutics (OTCMKTS:NWBO) last posted its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. The business had revenue of $0.81 million for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Northwest Biotherapeutics stock. Compass Financial Management LLC purchased a new stake in Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,215,500 shares of the biotechnology company’s stock, valued at approximately $227,000. Compass Financial Management LLC owned about 0.07% of Northwest Biotherapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 0.04% of the company’s stock.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc is a biotechnology company focused on developing personalized immunotherapies for cancer. Its technology uses a patient’s own dendritic cells, which are immune cells that can be prepared to recognize and target that individual’s tumor.

The company’s lead product candidate is DCVax-L, an autologous dendritic-cell vaccine designed for patients with glioblastoma, an aggressive form of brain cancer. Northwest Biotherapeutics has also investigated its platform in other solid tumors, including metastatic cancers, although DCVax-L has been the company’s primary clinical development program.

Northwest Biotherapeutics was founded in 1996 and is based in Bethesda, Maryland.